Latest news for Avatar Ventures (OTC:ATAR) Stock

Avatar Ventures Corp intends to be a developer of aftermarket electronic accessories for consumer motor vehicles.

AVATAR VENTURES CORP by Avatar Ventures Corp.

Avatar Ventures Corp

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics Inc

Atari SA

Atari Token

B of A Securities analyst Madeline Brooks downgrades Akamai Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) from Buy to Neutral and lowers the price target from $125 to $100.

News

Downgrades

Price Target

Analyst Ratings

AKAM

B of A Securities Downgrades Akamai Techs to Neutral, Lowers Price Target to $100

Needham analyst David Saxon maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $149 to $176.

GKOS

Needham Maintains Buy on Glaukos, Raises Price Target to $176

<a href="https://x.com/BillAckman/status/1892912458840547554" title="https://x.com/BillAckman/status/1892912458840547554">https://x.com/BillAckman/status/1892912458840547554</a>

Hedge Funds

General

Investor Bill Ackman, In Response To Wall Street Journal Report Of DoJ Investigation Into United Health's Medicare Billing Practices, Posted on X He Would Avoid The Stock

Needham analyst James Ricchiuti maintains Universal Display (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLED#NASDAQ">OLED</a>) with a Buy and lowers the price target from $215 to $170.

OLED

Needham Maintains Buy on Universal Display, Lowers Price Target to $170

HC Wainwright &amp; Co. analyst Ed Arce reiterates Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) with a Neutral and maintains $5.5 price target.

Reiteration

ARDX

HC Wainwright & Co. Reiterates Neutral on Ardelyx, Maintains $5.5 Price Target

United States Cellular (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.05) by 200 percent. This is a 68.75 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $970.00 million which beat the analyst consensus estimate of $965.87 million by 0.43 percent. This is a 3.00 percent decrease over sales of $1.00 billion the same period last year.

Earnings

Earnings Beats

United States Cellular Q4 2024 GAAP EPS $0.05 Beats $(0.05) Estimate, Sales $970.00M Beat $965.87M Estimate

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Buy and maintains $180 price target.

RGEN

HC Wainwright & Co. Reiterates Buy on Repligen, Maintains $180 Price Target

NIXX

Nixxy Enters Telecommunications And Data Sectors With AI Integration And Software Asset Purchase, Targets $5M Monthly Revenue In Q2

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">TDS Telecom</td>
<td colspan="1" rowspan="1">2025 Estimated Results</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Actual Results for the Year Ended December 31, 2024</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(Dollars in millions)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total operating revenues</td>
<td colspan="1" rowspan="1">$1,030-$1,070</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1,061</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted OIBDA (Non-GAAP)</td>
<td colspan="1" rowspan="1">$310-$350</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$340</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA&nbsp;(Non-GAAP)</td>
<td colspan="1" rowspan="1">$320-$360</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$350</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures</td>
<td colspan="1" rowspan="1">$375-$425</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$324</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Telephone and Data Systems' TDS Telecom Segment Expects FY25 Operating Revenue Of $1.03B-$1.07B Vs $1.06B YoY, Capex Of $320M-$360M Vs $350M YoY

Sunstone Hotel Investors Expects FY25 Adjusted FFO Per Share Of $0.86 - $0.98, Est $0.97

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Buy and maintains $28 price target.

BNTC

HC Wainwright & Co. Reiterates Buy on Benitec Biopharma, Maintains $28 Price Target

NCTY

The9 Forms Joint Venture With Chengdu Qing Cheng Network To Expand Mobile Game Operations In China's Sinking Market

Canaccord Genuity analyst Kyle Mikson maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Hold and raises the price target from $165 to $170.

Canaccord Genuity Maintains Hold on Repligen, Raises Price Target to $170

VMAR

Vision Marine Technologies Announced That Its Board Of Directors Has Approved Stock Repurchase Program Authorizing The Repurchase Of Up To 5% Of Company's Issued And Outstanding Common Shares As Of Today

Mizuho analyst Vijay Rakesh maintains Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) with a Neutral and raises the price target from $11 to $13.

RIVN

Mizuho Maintains Neutral on Rivian Automotive, Raises Price Target to $13

Sunstone Hotel Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHO#NYSE">SHO</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.14 by 14.29 percent. This is a 15.79 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $214.77 million which beat the analyst consensus estimate of $211.17 million by 1.70 percent. This is a 2.03 percent decrease over sales of $219.22 million the same period last year.

Sunstone Hotel Invts Q4 2024 Adjusted FFO Per Share $0.16 Beats $0.14 Estimate, Sales $214.77M Beat $211.17M Estimate

Earnings Misses

Telephone and Data Q4 2024 Adj. EPS $(0.09), Sales $1.240B Miss $1.254B Estimate

Canaccord Genuity analyst Kyle Rose maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $304 to $324.

PODD

Canaccord Genuity Maintains Buy on Insulet, Raises Price Target to $324

HC Wainwright &amp; Co. analyst Yi Chen maintains Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) with a Buy and lowers the price target from $23 to $20.

BLCO

HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Lowers Price Target to $20

Under the terms of the agreement, bluebird stockholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December 31, 2027, for a potential total value of up to $9.84 per share in cash, subject to the tender of a majority of the outstanding shares of bluebird, receipt of applicable regulatory approvals, and other customary closing conditions.

Comments

Avatar Ventures

News

Latest news for Avatar Ventures (OTC:ATAR) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga